©2025 Stanford Medicine
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer
Not Recruiting
Trial ID: NCT00564928
Purpose
To determine:
* Anti-tumor activity of IPI-504 in 2 groups of subjects with hormone resistant prostate cancer.
* Group A - subjects who have not previously received chemotherapy
* Group B - sujects who have received prior chemotherapy or could not tolerate chemotherapy.
* Clinical response will be determined by PSA and radiological response
Official Title
A Phase 2 Open-Label Study to Investigate the Pharmacodynamics and Clinical Activity of IPI-504 in Patients With Castration-Resistant Prostate Cancer Stratified by Prior Chemotherapy
Stanford Investigator(s)
Sandy Srinivas
Professor of Medicine (Oncology) and, by courtesy, of Urology
Eligibility
Inclusion Criteria:
* Adenocarcinoma of the prostate
* Resolution of acute toxic side effects of prior chemotherapy
* Castration resistant disease despite ongoing chemical or surgical castration
* ECOG 0-1
* PSA greater than or equal to 2
* Group A -
* No Prior treatment for prostate cancer with cytotoxic chemotherapy (neoadjuvant, adjuvant treatment permitted if more than 2 years out)
* Group B
* Radiographic evidence of metastatic disease
* Prior tx with docetaxel-minimum of 2 cycles with progression by RECIST or PSA or intolerant of tx
* Maximum of 3 prior chemotherapies
Exclusion Criteria:
* Small cell carcinoma of the prostate
* Treatment within 2 weeks with approved, investigational, or small molecule
* Treatment within 4 weeks with biologic or external beam radiation
* ANC \<1,500 cells m3; Platelets \<100,000 mm3; Hemoglobin \<9.0g/dL
* AST/ALT \>2.5 ULN
* Serum creatinine \>3.0mg/dL
* Active keratitis or keratoconjunctivitis
* Previous treatment with 17-AAG, DMAG; or any other HSP-90 inhibitor
* Baseline Qtc \>450 mses
Intervention(s):
drug: IPI-504
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Denise Haas
6507361252